Great news! Dr. Wang Tong, CSO of Shengshi Taikang, and Dr. Zhao Jiahong, CMO, have been named Gusu Leading Talents.

On December 23, 2021, Suzhou, China — Suzhou recently announced its second batch of Gusu Leading Talents for 2021. Dr. Tong Wang, CSO (Chief Scientific Officer) at Shengshi Taikang, and Dr. Jiahong Zhao, CMO (Chief Medical Officer), were both successfully selected as innovative leaders.

Dr. Wang Tong earned her bachelor’s degree in chemistry from Peking University and later went on to earn her PhD in chemistry from Syracuse University in the United States. With over two decades of comprehensive experience in drug discovery and development, as well as pharmaceutical management, Dr. Wang has worked at some of America’s leading pharmaceutical companies and research institutions. Prior to joining Shengshi Taikang, she held positions at Schering-Plough and the Translational Genomics Research Institute/Translational Drug Development Inc., where she led nearly ten groundbreaking global projects focused on developing first-in-class small-molecule drugs targeting areas such as cancer, immunology, ophthalmic diseases, and metabolic disorders. Notably, she successfully advanced four of these innovative drug programs into the clinical trial phase.

Dr. Wang Tong, CSO (Chief Scientific Officer) of Shengshi Taikang

Dr. Wang Tong has been recognized as a Class A Leading Talent in Innovation and Technology in Suzhou Industrial Park, an expert under the High-End Foreign Expert Recruitment Program, and holds the title of Senior Engineer. He has secured nearly 20 invention patents and published more than 10 academic papers.

Dr. Zhao Jiahong holds a medical doctorate from the School of Medicine at Fudan University and boasts over 20 years of expertise in pharmaceutical clinical trials, along with extensive experience in team management. He also has 6 years of hands-on clinical experience as an internal medicine hematologist and has taught at the medical school. Prior to joining Shengshi Taikang, Dr. Zhao served as Vice President and CMO at a major CRO company, where he oversaw more than 600 clinical trial projects. Notably, he successfully led the clinical development of three new blood product varieties, which have since been approved and launched onto the market. Additionally, he authored the drug instructions for seven products, which were subsequently selected by the National Pharmacopoeia Committee as the industry standard for blood products—standards that remain in use today. As an external expert, Dr. Zhao has actively contributed to the "7.22 Data Verification Task" organized by the National Medical Products Administration and the CDE, as well as played a key role in drafting and revising several technical guidance principles.

Dr. Zhao Jiahong, CMO (Chief Medical Officer) of Shengshi Taikang

Dr. Zhao Jiahong has been honored as a distinguished professor at Jiangsu University and Zhejiang University of Traditional Chinese Medicine, an external review expert for the CDE Biologics Committee, a contributing editor and reviewer for the journal *Central South Pharmacy*, a member of the Professional Committee on Research and Evaluation of Traditional Chinese Medicine Injections, and a pharmaceutical project review expert for several organizations including China’s Ministry of Science and Technology, Shanghai Municipal Science and Technology Commission, and Shanghai Municipal Health Commission—among more than ten prestigious titles and accolades.